Drugs / SHR-1906
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04986540 | Aug 2021 → Sep 2022 | idiopathic pulmonary fibrosis | Guangdong Hengrui Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05722964 | Mar 2023 → Aug 2024 | idiopathic pulmonary fibrosis | Guangdong Hengrui Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT04842630 Background | Apr 2021 → Nov 2022 | cancer of unknown primary site | Jiangsu HengRui Medicine Co., Ltd. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR-1906 | “All participants receive SHR-1906 alone” NCT04842630 ↗ |
| Route | Intravenous | “Drug: SHR-1906 IV, single dose” NCT04986540 ↗ |